Infective endocarditis
Also known as: endocarditis · endocarditis prophylaxis · IE
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications — A Scientific Statement for Healthcare Professionals From the American Heart Association
American Heart Association (AHA) · 2015
The AHA scientific statement describes diagnostic evaluation, antimicrobial treatment by causative organism, and management of complications of infective endocarditis in adults. It updates the earlier 2005 AHA statement.
2023 ESC Guidelines for the management of endocarditis
European Society of Cardiology (ESC) · 2023
The ESC guideline covers prevention, diagnosis, antimicrobial and surgical management, and follow-up of endocarditis, replacing the 2015 ESC document. It reflects developments in imaging, transcatheter valve procedures and outpatient treatment.
- The guideline revises risk categories and antibiotic prophylaxis indications and formalises the role of multidisciplinary endocarditis teams. source
- It adds guidance on identifying candidates for outpatient parenteral or oral antibiotic therapy and on managing cardiac device-associated infection. source
US vs EU key differences
- Version currency differs sharply: the US document is a 2015 AHA scientific statement, while the European guidance was fully rewritten as the 2023 ESC endocarditis guideline. source
- The 2023 ESC guideline endorses a two-phase antibiotic strategy — roughly two weeks of in-hospital intravenous therapy, then outpatient parenteral or oral completion in selected stabilised patients after TEE confirms no local progression; the 2015 AHA statement predates the partial-oral (POET) evidence. source
- The ESC formalises care organisation that the older AHA statement does not: a multidisciplinary Endocarditis Team (cardiology, imaging, cardiac surgery, infectious diseases, microbiology, OPAT) with complicated cases referred to designated Heart Valve Centres. source
- ESC 2023 restricts antibiotic prophylaxis to high-risk patients (prior endocarditis, prosthetic valves, complex congenital disease) undergoing oral-dental procedures, and explicitly states prophylaxis is not warranted to prevent cardiac implantable electronic device infection. source
What changed recently
- EU2015 → 20232023-08-25
The 2023 ESC edition upgraded antibiotic prophylaxis before invasive dental procedures in high-risk patients to a Class I recommendation, added a revised diagnostic algorithm built around multimodality imaging, and endorsed switching stabilised, uncomplicated patients to outpatient parenteral or oral antibiotic therapy. It also formalised management by a multidisciplinary Endocarditis Team based at heart valve centres.
- US2005 → 20152015-10-13
The 2015 AHA statement dropped adjunctive gentamicin from native-valve Staphylococcus aureus endocarditis regimens, since combination therapy added nephrotoxicity without clear benefit, leaving six weeks of single-agent anti-staphylococcal therapy. It also updated the epidemiology to reflect the rise of healthcare-associated and staphylococcal disease and reinforced early echocardiography plus at least three separately drawn blood culture sets.
source ↗curation confidence 90%
See the full update feed for changes across every system.